Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases

Current Pharmaceutical Design

Volumn 10, Issue 7, 2004, Pages 797-803

  Tomita, N ^a   Morishita, R ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antisense oligonucleotides; Gene expression; Gene therapy; Hypertension; Renin angiotensin system

Indexed keywords

ADENOSINE; ADENOVIRUS VECTOR; AGGLUTININ; ANGIOTENSIN; ANGIOTENSINOGEN; ANTISENSE OLIGONUCLEOTIDE; BETA GLOBIN; COMPLEMENTARY DNA; CYTIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ESTER DERIVATIVE; ETOMIDATE; GUANOSINE; HYDROGEN; LIPOSOME; MESSENGER RNA; MORPHOLINE DERIVATIVE; MYC PROTEIN; NAKED DNA; NUCLEASE; NUCLEIC ACID; PARVOVIRUS VECTOR; PEPTIDE NUCLEIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; PLASMID DNA; PROTEIN C MYB; RETROVIRUS VECTOR; RIBONUCLEASE H; RNA; THYMIDINE; UNINDEXED DRUG;

ANALYTIC METHOD; ANIMAL MODEL; BINDING AFFINITY; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMPLEX FORMATION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG ACTIVITY; DRUG BINDING; DRUG DEGRADATION; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG SPECIFICITY; DRUG STABILITY; ENZYMATIC DEGRADATION; ENZYME ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; REVIEW; RNA DEGRADATION; SIDE EFFECT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; THEORY; TREATMENT PLANNING; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARDIOVASCULAR DISEASES; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERTENSION; OLIGONUCLEOTIDES, ANTISENSE;

EID: 1442325589     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452965     Document Type: Review

References (70)

1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 289-94.
2. Stein C. Keeping the biotechnology of antisense in context. Nat Biotechnol 1999; 17: 209:
3. Dean NM, Cooper SR, Shanaham W, Taylor J, Myers K. Pharmacology of antisense oligonucleotides. J Clin Ligand Assay 2000; 23: 43-9.
4. Marcusson EG, Yacyshyn BR, Shanahan WR, Dean NM. Preclinical and clinical pharmacology of antisense oligonucleotides. Mol Biotechol 1999; 12: 1-11.
5. Kurreck J. Antisense technologies: Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
6. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Therapeut 2003; 99: 55-77.
7. Herdewijn P. Heterocyclic modifications of oligonucleotides and antisense techonology. Antisense Nucleic Acid Drug Dev 2000; 10: 297-310.
8. Mickefield J. Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr Med Chem 2001; 8: 1157-79.
9. Mercatante D, Sazani P, Kole R. Modification of alternative splicing pathways as a potential chemotherapy for cancer and other diseases. Curr Cancer Drug Targets 2001; 1: 211-30.
10. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochem Biophys Acta 1990; 1049: 99-125.
11. Shi Y, Fad A, Galleon A, Hutchinson HG, Vem P, Dodge G, et al. Transcatheter delivery of cmyc antisense oligomers reduced neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994; 90: 944-51.
12. Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis. Some critical considerations. Circulation 1995; 92: 1981-93.
13. Milligan JF, Matteucci MD, Martin JC. Current concepts in antisense drug design. J Med Chem 1993; 36: 1923-37.
14. Weintraub HM. Antisense RNA and DNA. Sci Am 1990; 262: 40-6.
15. Crooke RM. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design 1992; 6: 609-46.
16. Cohen JS. Antisense oligodeoxynucleotides as antiviral agents. Antiviral Res 1991; 16: 121-33.
17. Stein CA, Tonkinson JL, Yakubov L. Phosphorothioate oligodeoxynucleotides - antisense inhibitors of gene expression? Pharmacol Ther 1991; 52: 365-84.
18. Bolziau C, Kurfurst R, Cazenave C, Roig V, Thuong NT, Toulme JJ. Inhibition of translation initiation by antisense oligonucleotides via an RNase H independent mechanism. Nucleic Acid Res 1991; 19: 1113-9.
19. Kozak M. Influences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc Natl Acad Sci USA 1986; 83: 2850-4.
20. Wagner RW, Nishikura K. Cell cycle expression of RNA duplex unwindase activity in mammalian cells. Mol Cell Biol 1988; 8: 770-7.
21. Cazenave C, Chevrier M, Nguyen TT, Helene C. Rate of degradation of α-and β-oligodexynucleotiedes in Xenopus oocytes. Implications for anti messenger strategies. Nucleic Acid Res 1987; 15: 10507-21.
22. Dash P, Latan I, Knapp M, Kandel ER, Goelet P. Selective elimination of mRNAs in vivo: Complementary oligodeoxynucleotides promote RNA degradation by RNAse H like activity. Proc Natl Acad Sci USA 1987; 84: 7896-7900.
23. Dagle JM, Walder JA, Weeks DL, Target degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: Studies of An2 and cyclin in embryogenesis. Nucleic Acid Res 1990; 18: 4751-7.
24. McManaway ME, Neckers LM, Loke SL, Al-Nasser AA, Redner RL, Shiramizu BT, et al. Tumor-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 808-11.
25. Daum T, Engels JW, Mag M, Muth J, Lucking S, Schroder HC, et al. Antisense deoxynucleotide: Inhibitor of splicing of mRNA of human immunodeficiency virus. Intervirology 1992; 33: 65-75.
26. Bennett MR, Lindner V, Deblois D, Reidy MA, Schwartz SM. Effect of phosphorothioated oligonucleotides on neointima formation in the rat carotid artery. Dissectiong the mechanism of action. Arterioscler Thromb Vasc Biol 1997; 17: 2326-32.
27. Bischofberger N, Wagner RW. Antisense approaches to antiviral agents. Semin Virol 1992; 3: 57-66.
28. Morvan F, Porumb H, Degols G, Lefebvre I, Pompon A, Sproat BS, et al. Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J Med Chem 1993; 36: 280-7.
29. Bennett FC, Chiang MY, Chan HC, Shoemaker JEE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41: 1023-33.
30. Wagner RW, Mtteucci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC. Antisense gene inhibition by oligonucleotides containing C-5 propene pyrimidines. Science 1993; 260: 1510-3.
31. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian Y, Bayewitch LA, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism. Proc Natl Acad Sci USA 1995; 92: 4051-5.
32. Manoharan M. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1999; 1489: 117-30.
33. Kole R, Sazani P. Antisense effects in the cell nucleus: modification of splicing. Curr Opin Mol Ther 2001; 3: 229-34.
34. Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 53-68.
35. Obika S, Uneda T, Sugimoto T, Nanbu D, Minami T, Doi T, et al. 2′-O, 4′-C-Methylene bridged nucleic acid (2′, 4′-BNA): synthesis and triplex-forming properties. Bioorg Med Chem 2001; 9: 1001-11.
36. Torigoe H, Hari Y, Sekiguchi M, Obika S, Imanishi T. 2′-O, 4′-C-methylene bridged nucleic acid modification promotes pyrimidine motif triplex DNA formation at physiological pH. Thermodynamic and kinetic studies. J Biol Chem 2001; 276: 2354-60.
37. Morita K, Hasegawa C, Kaneko M, Tsutsumi S, Sone J, Ishikawa T, et al. 2′-O, 4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett 2002; 12: 73-6.
38. Gryanov SM. Oligonucleotide N3′-P5′ phosphoramidates as potential therapeutic agents. Biochim Biophys Acta 1999; 1489: 131-40.
39. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1999; 1489: 141-58.
40. Elayadi AN, Corey DR. Application of PNA and LNA oligomers to chemotherapy. Curr Opin Investig Drugs 2001; 2: 558-61.
41. Declercq R, Van Aerschot A, Read RJ, Herdewijn P, Van Meervelt L. Crystal structure of double helical hexitol nucleic acids. J Am Chem Soc 2002; 124: 928-33.
42. Sproat BS. Chemistry and applications of oligonucleotide analogs. J Biotechnol 1995; 41: 221-38.
43. Vlassov VV, Vlassova IE, Pautova LV. Oligonucleotides and polynucleotides as biologically active compounds. Progress Nucleic Acid Research Molecular Biol 1997; 57: 95-143.
44. Sekine M, Tsuruoka H, Shohda KI, Moriguchi T, Wada T. New strategies for the chemical synthesis of biologically important nucleic acid derivatives. Nucleotides 1998; 17: 2033-43.
45. Verma S, Eckstein F. Modified oligonucteotides: Synthesis and strategy for users. Annu Rev Biochem 1998; 67: 99-134.
46. Caruthers MH. Gene synthesis machines: DNA chemistry and its uses. Science 1985; 230: 281-5.
47. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA co-introduced with nuclear protein in adult rat liver. Science 1989; 243: 375-8.
48. Kaneda Y, Iwai K, Uchida T. Introduction and expression of the human insulin gene in adult rat liver. J Biol Chem 1989; 264: 12126-9.
49. Tomita N, Higaki J, Morishita R, Kato K, Mikami H, Kaneda Y, et al. Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 1992; 186: 129-34.
50. Tomita N, Higaki J, Kaneda Y, Yu H, Morishita R, Mikami H, et al. Hypertensive rats produced by in vivo introduction of the human renin gene. Circ Res 1993; 73: 898-905.
51. Kaneda Y, Morishita R, Tomita N. Increased expression of DNA co-introduced with nuclear protein in adult rat liver. J Mol Med 1995; 73: 289-97.
52. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93: 11421-5.
53. Morishita R, Gibbons GH, Pratt RE, Tomita N, Kaneda Y, Ogihara T, et al. Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest 1994; 94: 824-9.
54. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today 1999; 5: 298-303.
55. Aoki M, Morishita R, Higaki J, Moriguchi A, Hayashi S, Matsushita H, et al. Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and the beta-galactosidase gene in the non-infarcted area, but not the myocardial infarcted area. Gene Ther 1997; 4: 120-7.
56. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8.
57. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 1994; 149: 13-9.
58. Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995; 26: 131-6.
59. Tomita N, Morishita R, Higaki J, Tomita S, Aoki M, Kaneda Y, et al. Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach. J Hypertens 1995; 13: 1767-74.
60. Morishita R, Gibbons GH, Tomita N, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function. Arterioscler Thromb Vasc Biol 2000; 20: 915-22.
61. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-9.
62. Tomita N, Morishita R, Higaki J, Ogihara T. Strategy for functional inactivation of genes: A novel strategy for gene therapy and gene regulation analysis using transcription factor decoy oligonucleotides. Exp Nephrol 1997; 5: 429-34.
63. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappa B binding site prevents myocardial infarction. Nat Med 1997; 3: 894-9.
64. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor decoy strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82: 1023-8.
65. Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim JY, Baran D, et al. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am J Physiol 1998; 27: F278-84.
66. Tomita N, Morishita R, Lan HY, Yamamoto K, Hashizume M, Notake M, et al. In vivo administration of a nuclear transcription factor-kappa B decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephro 12000; 11: 1244-52.
67. Tomita N, Morishita R, Tomita S, Gibbons GH, Zhang L, Horiuchi M, et al. Transcription factor decoy for NF-kappa B inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. Gene Ther 2000; 7: 1326-32.
68. Gambari R. Peptide-nucleic acids (PNAs): a tool for the development of gene expression modifiers. Curr Pharm Design 2001; 7(17): 1839-62.
69. Kurowska E. M. Nitric oxide therapies in vascular diseases. Curr Pharm Design 2002; 8(3): 155-66.
70. Younes C. K, Boisgard R, Tavitian B. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Design 2002; 8(16): 1451-66.